Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.
Identifieur interne : 000502 ( PubMed/Corpus ); précédent : 000501; suivant : 000503Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.
Auteurs : Priya S. Kishnani ; Eric T. Rush ; Paul Arundel ; Nick Bishop ; Kathryn Dahir ; William Fraser ; Paul Harmatz ; Agnès Linglart ; Craig F. Munns ; Mark E. Nunes ; Howard M. Saal ; Lothar Seefried ; Keiichi OzonoSource :
- Molecular genetics and metabolism [ 1096-7206 ] ; 2017.
Abstract
Hypophosphatasia (HPP) is a rare, inherited, systemic, metabolic disorder caused by autosomal recessive mutations or a single dominant-negative mutation in the gene encoding tissue-nonspecific alkaline phosphatase (TNSALP). The disease is associated with a broad range of signs, symptoms, and complications, including impaired skeletal mineralization, altered calcium and phosphate metabolism, recurrent fractures, pain, respiratory problems, impaired growth and mobility, premature tooth loss, developmental delay, and seizures. Asfotase alfa is a human, recombinant enzyme replacement therapy that is approved in many countries for the treatment of patients with HPP. To address the unmet need for guidance in the monitoring of patients receiving asfotase alfa, an international panel of physicians with experience in diagnosing and managing HPP convened in May 2016 to discuss treatment monitoring parameters. The panel discussions focused on recommendations for assessing and monitoring patients after the decision to treat with asfotase alfa had been made and did not include recommendations for whom to treat. Based on the consensus of panel members, this review provides guidance on the monitoring of patients with HPP during treatment with asfotase alfa, including recommendations for laboratory, efficacy, and safety assessments and the frequency with which these should be performed during the course of treatment. Recommended assessments are based on patient age and include regular monitoring of biochemistry, skeletal radiographs, respiratory function, growth, pain, mobility and motor function, and quality of life. Because of the systemic presentation of HPP, a coordinated, multidisciplinary, team-based, patient-focused approach is recommended in the management of patients receiving asfotase alfa. Monitoring of efficacy and safety outcomes must be tailored to the individual patient, depending on medical history, clinical manifestations, availability of resources in the clinical setting, and the clinician's professional judgment.
DOI: 10.1016/j.ymgme.2017.07.010
PubMed: 28888853
Links to Exploration step
pubmed:28888853Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.</title><author><name sortKey="Kishnani, Priya S" sort="Kishnani, Priya S" uniqKey="Kishnani P" first="Priya S" last="Kishnani">Priya S. Kishnani</name><affiliation><nlm:affiliation>Division of Medical Genetics, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: priya.kishnani@duke.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Rush, Eric T" sort="Rush, Eric T" uniqKey="Rush E" first="Eric T" last="Rush">Eric T. Rush</name><affiliation><nlm:affiliation>Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE 68198, USA(2).</nlm:affiliation></affiliation></author><author><name sortKey="Arundel, Paul" sort="Arundel, Paul" uniqKey="Arundel P" first="Paul" last="Arundel">Paul Arundel</name><affiliation><nlm:affiliation>Metabolic Bone Team, Sheffield Children's NHS Foundation Trust, Sheffield S10 2TH, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Bishop, Nick" sort="Bishop, Nick" uniqKey="Bishop N" first="Nick" last="Bishop">Nick Bishop</name><affiliation><nlm:affiliation>Academic Unit of Child Health, University of Sheffield and Sheffield Children's Hospital, Sheffield S10 2TH, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Dahir, Kathryn" sort="Dahir, Kathryn" uniqKey="Dahir K" first="Kathryn" last="Dahir">Kathryn Dahir</name><affiliation><nlm:affiliation>Division of Diabetes and Endocrinology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Fraser, William" sort="Fraser, William" uniqKey="Fraser W" first="William" last="Fraser">William Fraser</name><affiliation><nlm:affiliation>Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich NR4 7UY, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Harmatz, Paul" sort="Harmatz, Paul" uniqKey="Harmatz P" first="Paul" last="Harmatz">Paul Harmatz</name><affiliation><nlm:affiliation>Pediatric Gastroenterology and Nutrition, UCSF Benioff Children's Hospital Oakland, Oakland, CA 94609, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Linglart, Agnes" sort="Linglart, Agnes" uniqKey="Linglart A" first="Agnès" last="Linglart">Agnès Linglart</name><affiliation><nlm:affiliation>Service d'Endocrinologie Pédiatrique, Hôpital Bicêtre Paris-Sud, APHP, 94270 Le Kremlin Bicêtre, France.</nlm:affiliation></affiliation></author><author><name sortKey="Munns, Craig F" sort="Munns, Craig F" uniqKey="Munns C" first="Craig F" last="Munns">Craig F. Munns</name><affiliation><nlm:affiliation>Paediatrics & Child Health, The Children's Hospital at Westmead, Westmead, NSW 2145, Australia; Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Nunes, Mark E" sort="Nunes, Mark E" uniqKey="Nunes M" first="Mark E" last="Nunes">Mark E. Nunes</name><affiliation><nlm:affiliation>Department of Pediatrics, University of California, San Diego, San Diego, CA 92093, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Saal, Howard M" sort="Saal, Howard M" uniqKey="Saal H" first="Howard M" last="Saal">Howard M. Saal</name><affiliation><nlm:affiliation>Division of Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Seefried, Lothar" sort="Seefried, Lothar" uniqKey="Seefried L" first="Lothar" last="Seefried">Lothar Seefried</name><affiliation><nlm:affiliation>Orthopedic Department, University of Würzburg, Würzburg, Bavaria 97074, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Ozono, Keiichi" sort="Ozono, Keiichi" uniqKey="Ozono K" first="Keiichi" last="Ozono">Keiichi Ozono</name><affiliation><nlm:affiliation>Department of Pediatrics, Osaka University, Suita, Osaka 565-0871, Japan.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28888853</idno><idno type="pmid">28888853</idno><idno type="doi">10.1016/j.ymgme.2017.07.010</idno><idno type="wicri:Area/PubMed/Corpus">000502</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000502</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.</title><author><name sortKey="Kishnani, Priya S" sort="Kishnani, Priya S" uniqKey="Kishnani P" first="Priya S" last="Kishnani">Priya S. Kishnani</name><affiliation><nlm:affiliation>Division of Medical Genetics, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: priya.kishnani@duke.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Rush, Eric T" sort="Rush, Eric T" uniqKey="Rush E" first="Eric T" last="Rush">Eric T. Rush</name><affiliation><nlm:affiliation>Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE 68198, USA(2).</nlm:affiliation></affiliation></author><author><name sortKey="Arundel, Paul" sort="Arundel, Paul" uniqKey="Arundel P" first="Paul" last="Arundel">Paul Arundel</name><affiliation><nlm:affiliation>Metabolic Bone Team, Sheffield Children's NHS Foundation Trust, Sheffield S10 2TH, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Bishop, Nick" sort="Bishop, Nick" uniqKey="Bishop N" first="Nick" last="Bishop">Nick Bishop</name><affiliation><nlm:affiliation>Academic Unit of Child Health, University of Sheffield and Sheffield Children's Hospital, Sheffield S10 2TH, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Dahir, Kathryn" sort="Dahir, Kathryn" uniqKey="Dahir K" first="Kathryn" last="Dahir">Kathryn Dahir</name><affiliation><nlm:affiliation>Division of Diabetes and Endocrinology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Fraser, William" sort="Fraser, William" uniqKey="Fraser W" first="William" last="Fraser">William Fraser</name><affiliation><nlm:affiliation>Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich NR4 7UY, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Harmatz, Paul" sort="Harmatz, Paul" uniqKey="Harmatz P" first="Paul" last="Harmatz">Paul Harmatz</name><affiliation><nlm:affiliation>Pediatric Gastroenterology and Nutrition, UCSF Benioff Children's Hospital Oakland, Oakland, CA 94609, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Linglart, Agnes" sort="Linglart, Agnes" uniqKey="Linglart A" first="Agnès" last="Linglart">Agnès Linglart</name><affiliation><nlm:affiliation>Service d'Endocrinologie Pédiatrique, Hôpital Bicêtre Paris-Sud, APHP, 94270 Le Kremlin Bicêtre, France.</nlm:affiliation></affiliation></author><author><name sortKey="Munns, Craig F" sort="Munns, Craig F" uniqKey="Munns C" first="Craig F" last="Munns">Craig F. Munns</name><affiliation><nlm:affiliation>Paediatrics & Child Health, The Children's Hospital at Westmead, Westmead, NSW 2145, Australia; Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Nunes, Mark E" sort="Nunes, Mark E" uniqKey="Nunes M" first="Mark E" last="Nunes">Mark E. Nunes</name><affiliation><nlm:affiliation>Department of Pediatrics, University of California, San Diego, San Diego, CA 92093, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Saal, Howard M" sort="Saal, Howard M" uniqKey="Saal H" first="Howard M" last="Saal">Howard M. Saal</name><affiliation><nlm:affiliation>Division of Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Seefried, Lothar" sort="Seefried, Lothar" uniqKey="Seefried L" first="Lothar" last="Seefried">Lothar Seefried</name><affiliation><nlm:affiliation>Orthopedic Department, University of Würzburg, Würzburg, Bavaria 97074, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Ozono, Keiichi" sort="Ozono, Keiichi" uniqKey="Ozono K" first="Keiichi" last="Ozono">Keiichi Ozono</name><affiliation><nlm:affiliation>Department of Pediatrics, Osaka University, Suita, Osaka 565-0871, Japan.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Molecular genetics and metabolism</title><idno type="eISSN">1096-7206</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Hypophosphatasia (HPP) is a rare, inherited, systemic, metabolic disorder caused by autosomal recessive mutations or a single dominant-negative mutation in the gene encoding tissue-nonspecific alkaline phosphatase (TNSALP). The disease is associated with a broad range of signs, symptoms, and complications, including impaired skeletal mineralization, altered calcium and phosphate metabolism, recurrent fractures, pain, respiratory problems, impaired growth and mobility, premature tooth loss, developmental delay, and seizures. Asfotase alfa is a human, recombinant enzyme replacement therapy that is approved in many countries for the treatment of patients with HPP. To address the unmet need for guidance in the monitoring of patients receiving asfotase alfa, an international panel of physicians with experience in diagnosing and managing HPP convened in May 2016 to discuss treatment monitoring parameters. The panel discussions focused on recommendations for assessing and monitoring patients after the decision to treat with asfotase alfa had been made and did not include recommendations for whom to treat. Based on the consensus of panel members, this review provides guidance on the monitoring of patients with HPP during treatment with asfotase alfa, including recommendations for laboratory, efficacy, and safety assessments and the frequency with which these should be performed during the course of treatment. Recommended assessments are based on patient age and include regular monitoring of biochemistry, skeletal radiographs, respiratory function, growth, pain, mobility and motor function, and quality of life. Because of the systemic presentation of HPP, a coordinated, multidisciplinary, team-based, patient-focused approach is recommended in the management of patients receiving asfotase alfa. Monitoring of efficacy and safety outcomes must be tailored to the individual patient, depending on medical history, clinical manifestations, availability of resources in the clinical setting, and the clinician's professional judgment.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28888853</PMID><DateCreated><Year>2017</Year><Month>09</Month><Day>10</Day></DateCreated><DateRevised><Year>2017</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-7206</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>1-2</Issue><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Molecular genetics and metabolism</Title><ISOAbbreviation>Mol. Genet. Metab.</ISOAbbreviation></Journal><ArticleTitle>Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.</ArticleTitle><Pagination><MedlinePgn>4-17</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1096-7192(16)30374-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ymgme.2017.07.010</ELocationID><Abstract><AbstractText>Hypophosphatasia (HPP) is a rare, inherited, systemic, metabolic disorder caused by autosomal recessive mutations or a single dominant-negative mutation in the gene encoding tissue-nonspecific alkaline phosphatase (TNSALP). The disease is associated with a broad range of signs, symptoms, and complications, including impaired skeletal mineralization, altered calcium and phosphate metabolism, recurrent fractures, pain, respiratory problems, impaired growth and mobility, premature tooth loss, developmental delay, and seizures. Asfotase alfa is a human, recombinant enzyme replacement therapy that is approved in many countries for the treatment of patients with HPP. To address the unmet need for guidance in the monitoring of patients receiving asfotase alfa, an international panel of physicians with experience in diagnosing and managing HPP convened in May 2016 to discuss treatment monitoring parameters. The panel discussions focused on recommendations for assessing and monitoring patients after the decision to treat with asfotase alfa had been made and did not include recommendations for whom to treat. Based on the consensus of panel members, this review provides guidance on the monitoring of patients with HPP during treatment with asfotase alfa, including recommendations for laboratory, efficacy, and safety assessments and the frequency with which these should be performed during the course of treatment. Recommended assessments are based on patient age and include regular monitoring of biochemistry, skeletal radiographs, respiratory function, growth, pain, mobility and motor function, and quality of life. Because of the systemic presentation of HPP, a coordinated, multidisciplinary, team-based, patient-focused approach is recommended in the management of patients receiving asfotase alfa. Monitoring of efficacy and safety outcomes must be tailored to the individual patient, depending on medical history, clinical manifestations, availability of resources in the clinical setting, and the clinician's professional judgment.</AbstractText><CopyrightInformation>Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kishnani</LastName><ForeName>Priya S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Division of Medical Genetics, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: priya.kishnani@duke.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rush</LastName><ForeName>Eric T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE 68198, USA(2).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arundel</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Metabolic Bone Team, Sheffield Children's NHS Foundation Trust, Sheffield S10 2TH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bishop</LastName><ForeName>Nick</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Academic Unit of Child Health, University of Sheffield and Sheffield Children's Hospital, Sheffield S10 2TH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahir</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Diabetes and Endocrinology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich NR4 7UY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harmatz</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pediatric Gastroenterology and Nutrition, UCSF Benioff Children's Hospital Oakland, Oakland, CA 94609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linglart</LastName><ForeName>Agnès</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service d'Endocrinologie Pédiatrique, Hôpital Bicêtre Paris-Sud, APHP, 94270 Le Kremlin Bicêtre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munns</LastName><ForeName>Craig F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Paediatrics & Child Health, The Children's Hospital at Westmead, Westmead, NSW 2145, Australia; Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nunes</LastName><ForeName>Mark E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California, San Diego, San Diego, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saal</LastName><ForeName>Howard M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Division of Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seefried</LastName><ForeName>Lothar</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Orthopedic Department, University of Würzburg, Würzburg, Bavaria 97074, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozono</LastName><ForeName>Keiichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Osaka University, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Genet Metab</MedlineTA><NlmUniqueID>9805456</NlmUniqueID><ISSNLinking>1096-7192</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alkaline phosphatase</Keyword><Keyword MajorTopicYN="N">Asfotase alfa</Keyword><Keyword MajorTopicYN="N">Enzyme replacement therapy</Keyword><Keyword MajorTopicYN="N">Hypophosphatasia</Keyword><Keyword MajorTopicYN="N">Metabolic bone diseases</Keyword><Keyword MajorTopicYN="N">Therapeutic drug monitoring</Keyword><Keyword MajorTopicYN="N">Tissue-nonspecific alkaline phosphatase</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>07</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>07</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28888853</ArticleId><ArticleId IdType="pii">S1096-7192(16)30374-2</ArticleId><ArticleId IdType="doi">10.1016/j.ymgme.2017.07.010</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000502 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000502 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28888853
|texte= Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28888853" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |